VEGFA and neoplasm: Antiangiogenic or immunogenic drugs are useful in tumor recurrence, such as bevacizumab, a monoclonal antibody that blocks angiogenesis by inhibiting endothelial growth factor A (VEGF-A), which is expressed in excess in 94% of the patients with AGCT [9,12,13].